CD47 overexpression has been reported in various types of malignancy and is associated with a poor prognosis in solid and hematologic malignancies, including non-small cell lung cancer, breast cancer, stomach cancer, and non-Hodgkin lymphoma [13,14,15,16]. Here, CD47 is linked to breast carcinoma.